Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies

Reference

1. 1.↵
   International Conference on Harmonisation (ICH) Technical Requirements for Registration of Pharmaceuticals for Human Use. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Q5A (R1). Geneva, Switzerland, 1998.
2. 2.↵
   1. Lie Y. S.,
   2. Penuel E. M.,
   3. Low M.A.,
   4. Nguyen T.P.,
   5. Mangahas J.O.,
   6. Anderson K.P.,
   7. Petropoulos C.J.

   Chinese hamster ovary cells contain transcriptionally active full-length type c proviruses. J. Virol 1994, 68 (12), 7840–7849.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Anderson K.P.,
   2. Low M.A.,
   3. Lie Y.S.,
   4. Keller G.A.,
   5. Dinowitz M.

   Endogenous origin of defective retrovirus-like particles from a recombinant chinese hamster ovary cell line. J. Virol 1991, 181, 305–311.

   OpenUrl
4. 4.↵
   1. Lewis N.E.,
   2. Liu X.,
   3. Li Y.,
   4. Nagarajan H.,
   5. Yerganian G.,
   6. O'Brien E.,
   7. Bordbar A.,
   8. Roth A.M.,
   9. Rosenbloom J.,
   10. Bian C.,
   11. Xie M.,
   12. Chen W.,
   13. Li N.,
   14. Baycin-Hizal D.,
   15. Latif H.,
   16. Forster J.,
   17. Betenbaugh M.J.,
   18. Famili I.,
   19. Xu X.,
   20. Wang J.,
   21. Palsson B.O.

   Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nature Biotech 2013, 31 (8), 759–765.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. de Wit C.,
   2. Corinne F.,
   3. Xu Y.

   Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. Biologicals 2000, 28, 137–148.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Zhan D.,
   2. Roy. M.R.,
   3. Valera C.,
   4. Cardenas J.,
   5. Vennari J.C.,
   6. Chen J.W.,
   7. Liu S.

   Detection of minute virus of mice using real time quantitative PCR in assessment of virus clearance during the purification of Mammalian cell substrate derived biotherapeutics. Biologicals 2002, 30, 259–270.

   OpenUrlPubMed
7. 7.↵
   1. Blümel J.,
   2. Brorson K.

   2015 Viral clearance symposium session 2: company-specific data on cycled resin testing. PDA J. Pharm. Sci. and Tech 2016, 70, 428–442.

   OpenUrl
8. 8.↵
   FDA Points to consider in the characterization of cell lines used to produce biologicals (1997), available at https://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/ucm162863.pdf.
9. 9.↵
   Guideline on virus safety evaluation of biotechnological investigational medicinal products (EMEA/CHMP/BWP/398498/2005), accessed July 2008.
10. 10.↵
    1. Gefroh E.,
    2. Dehghani H.,
    3. McClure M.,
    4. Connell-Crowley L.,
    5. Vedantham G.

    Use of MVM as a single worst-case model virus in viral filter validation studies. PDA J. Pharm. Sci. and Tech 2014, 68, 297–311.

    OpenUrl
11. 11.↵
    ASTM E2888–12, Standard practice for process for inactivation of rodent retrovirus by pH; available at www.astm.org.
12. 12.↵
    1. Brorson K.,
    2. Campbell J.,
    3. Carter J.,
    4. Dolan S.,
    5. Krishnan M.,
    6. Lute S.,
    7. Martin J.,
    8. Haque M.,
    9. Morgan M.,
    10. Sato T.,
    11. Sofer G.,
    12. Sundaram S.,
    13. Tarrach K.

    Technical Report No. 41 Revised 2008 Virus Filtration. PDA J. Pharm. Sci. and Tech. Supplement to the PDA Journal of Pharmaceutical Science and Technology 2008, 62, S–4.
13. 13.↵
    1. Zhang M.,
    2. Lute S,
    3. Norling L.,
    4. Hong C.,
    5. Safta A.,
    6. O'Connor D.,
    7. Bernstein L.J.,
    8. Wang H.,
    9. Blank G.,
    10. Brorson K.,
    11. Chen Q.

    A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture Protein A chromatography. Biotechnol. Bioeng 2009, 102, 1438–1447.

    OpenUrlPubMed
14. 14.↵
    Guideline on plasma-derived medicinal products (EMA/CHMP/BWP/706271/2010), July 2011.